Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
Executive Summary
Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.
You may also be interested in...
Zika Vaccine Trials Could Test Multiple Candidates Vs. Common Control Group
FDA and NIH officials propose three strategies for clinical trials, saying it will be challenging to identify the most promising candidates; Sanofi and Walter Reed researchers note challenges in vaccine development, including manufacturing scale up.
Takeda-Zydus Enter Increasingly Crowded Chikungunya Fray
Takeda and Zydus Cadila are stepping into the fray to develop a vaccine for chikungunya, an increasingly crowded segment that now has over a dozen candidates in various stages of development.
Takeda Gains On Sanofi As Two-Shot Dengue Vaccine Advances
While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.